What causes epigastric pain in patients with severe ADAMTS13 deficiency?

Epigastric Pain in ADAMTS13 Deficiency

Epigastric pain in patients with severe ADAMTS13 deficiency results from ischemic organ damage caused by microvascular thrombosis affecting the gastrointestinal tract, particularly involving the pancreas, liver, and mesenteric vasculature.

Pathophysiological Mechanism

The underlying mechanism is straightforward: severe ADAMTS13 deficiency (activity <10%) leads to accumulation of ultra-large von Willebrand factor (UL-VWF) multimers, which trigger excessive platelet adhesion and aggregation throughout the microvasculature 1. This microvascular thrombosis causes ischemic damage to end organs, including the gastrointestinal system 2.

Specific Gastrointestinal Manifestations

The epigastric pain represents:

• Mesenteric ischemia from microthrombosis in splanchnic vessels
• Pancreatic involvement with potential pancreatitis-like presentation
• Hepatic ischemia from microthrombi in hepatic sinusoids
• Gastric/duodenal mucosal ischemia from capillary thrombosis

Clinical Context

This occurs as part of the broader TTP syndrome, where patients present with:

• Severe thrombocytopenia (typically <30 × 10⁹/L)
• Microangiopathic hemolytic anemia (elevated LDH, schistocytes, low hemoglobin)
• Variable degrees of end-organ damage affecting multiple systems 1

The epigastric pain is not an isolated symptom but rather one manifestation of widespread microvascular thrombosis affecting multiple organ systems simultaneously 2.

Critical Diagnostic Considerations

The key pitfall is that epigastric pain may occur even when complete hematological abnormalities are not yet present. Recent evidence demonstrates that severe ADAMTS13 deficiency can cause organ ischemia, including stroke, without concurrent severe thrombocytopenia or microangiopathic hemolytic anemia 3. This means:

• Do not wait for the classic "pentad" to consider TTP
• Abdominal symptoms may precede full hematological manifestations
• ADAMTS13 testing should be performed when TTP is suspected clinically, even with borderline laboratory findings

Immediate Clinical Approach

When encountering epigastric pain with suspected ADAMTS13 deficiency:

1. Obtain ADAMTS13 activity level immediately - diagnosis requires activity <10 IU/dL 2
2. Do not wait for results to initiate treatment if clinical suspicion is high - turnaround time can be 2-4 days 4
3. Use clinical scoring systems (French score or PLASMIC score) to assess likelihood of severe ADAMTS13 deficiency while awaiting confirmatory testing 1

Treatment Implications

For immune TTP (iTTP) with acute presentation including epigastric pain:

• Initiate plasma exchange, corticosteroids, and caplacizumab immediately 5
• This reduces mortality from 15.7% to 3.9% compared to delayed treatment 5

For congenital TTP (cTTP):

• Recombinant ADAMTS13 is now first-line prophylaxis 1
• Fresh frozen plasma if recombinant ADAMTS13 unavailable 1

The epigastric pain will resolve with restoration of ADAMTS13 activity and resolution of microvascular thrombosis, but permanent organ damage may occur if treatment is delayed 6.